226 related articles for article (PubMed ID: 28448979)
1. Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis.
Lopes-Pacheco M; Boinot C; Sabirzhanova I; Rapino D; Cebotaru L
Cell Physiol Biochem; 2017; 41(6):2194-2210. PubMed ID: 28448979
[TBL] [Abstract][Full Text] [Related]
2. Correctors Rescue CFTR Mutations in Nucleotide-Binding Domain 1 (NBD1) by Modulating Proteostasis.
Lopes-Pacheco M; Sabirzhanova I; Rapino D; Morales MM; Guggino WB; Cebotaru L
Chembiochem; 2016 Mar; 17(6):493-505. PubMed ID: 26864378
[TBL] [Abstract][Full Text] [Related]
3. Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation.
Rapino D; Sabirzhanova I; Lopes-Pacheco M; Grover R; Guggino WB; Cebotaru L
PLoS One; 2015; 10(3):e0119796. PubMed ID: 25799511
[TBL] [Abstract][Full Text] [Related]
4. Correcting the cystic fibrosis disease mutant, A455E CFTR.
Cebotaru L; Rapino D; Cebotaru V; Guggino WB
PLoS One; 2014; 9(1):e85183. PubMed ID: 24416359
[TBL] [Abstract][Full Text] [Related]
5. Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27.
Lopes-Pacheco M; Boinot C; Sabirzhanova I; Morales MM; Guggino WB; Cebotaru L
J Biol Chem; 2015 Oct; 290(42):25636-45. PubMed ID: 26336106
[TBL] [Abstract][Full Text] [Related]
6. The PEST sequence does not contribute to the stability of the cystic fibrosis transmembrane conductance regulator.
Chen EY; Clarke DM
BMC Biochem; 2002 Oct; 3():29. PubMed ID: 12361483
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis transmembrane regulator missing the first four transmembrane segments increases wild type and DeltaF508 processing.
Cebotaru L; Vij N; Ciobanu I; Wright J; Flotte T; Guggino WB
J Biol Chem; 2008 Aug; 283(32):21926-33. PubMed ID: 18508776
[TBL] [Abstract][Full Text] [Related]
8. Derlin-1 promotes the efficient degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants.
Sun F; Zhang R; Gong X; Geng X; Drain PF; Frizzell RA
J Biol Chem; 2006 Dec; 281(48):36856-63. PubMed ID: 16954204
[TBL] [Abstract][Full Text] [Related]
9. CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine.
McDonald EF; Meiler J; Plate L
ACS Chem Biol; 2023 Oct; 18(10):2128-2143. PubMed ID: 37730207
[TBL] [Abstract][Full Text] [Related]
10. Correctors promote folding of the CFTR in the endoplasmic reticulum.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2008 Jul; 413(1):29-36. PubMed ID: 18361776
[TBL] [Abstract][Full Text] [Related]
11. Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator.
Xiong X; Bragin A; Widdicombe JH; Cohn J; Skach WR
J Clin Invest; 1997 Sep; 100(5):1079-88. PubMed ID: 9276724
[TBL] [Abstract][Full Text] [Related]
12. Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited.
Chen EY; Bartlett MC; Clarke DM
Biochemistry; 2000 Apr; 39(13):3797-803. PubMed ID: 10736180
[TBL] [Abstract][Full Text] [Related]
13. The mechanism underlying cystic fibrosis transmembrane conductance regulator transport from the endoplasmic reticulum to the proteasome includes Sec61beta and a cytosolic, deglycosylated intermediary.
Bebök Z; Mazzochi C; King SA; Hong JS; Sorscher EJ
J Biol Chem; 1998 Nov; 273(45):29873-8. PubMed ID: 9792704
[TBL] [Abstract][Full Text] [Related]
14. Repair of CFTR folding defects with correctors that function as pharmacological chaperones.
Loo TW; Clarke DM
Methods Mol Biol; 2011; 741():23-37. PubMed ID: 21594776
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications.
Vij N; Fang S; Zeitlin PL
J Biol Chem; 2006 Jun; 281(25):17369-17378. PubMed ID: 16621797
[TBL] [Abstract][Full Text] [Related]
16. Rescue of defective ATP8B1 trafficking by CFTR correctors as a therapeutic strategy for familial intrahepatic cholestasis.
van der Woerd WL; Wichers CG; Vestergaard AL; Andersen JP; Paulusma CC; Houwen RH; van de Graaf SF
J Hepatol; 2016 Jun; 64(6):1339-47. PubMed ID: 26879107
[TBL] [Abstract][Full Text] [Related]
17. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
[No Abstract] [Full Text] [Related]
18. The CFTR Corrector, VX-809 (Lumacaftor), Rescues ABCA4 Trafficking Mutants: a Potential Treatment for Stargardt Disease.
Liu Q; Sabirzhanova I; Bergbower EAS; Yanda M; Guggino WG; Cebotaru L
Cell Physiol Biochem; 2019; 53(2):400-412. PubMed ID: 31403270
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator degradation: cross-talk between the ubiquitylation and SUMOylation pathways.
Ahner A; Gong X; Frizzell RA
FEBS J; 2013 Sep; 280(18):4430-8. PubMed ID: 23809253
[TBL] [Abstract][Full Text] [Related]
20. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi.
Farinha CM; Matos P; Amaral MD
FEBS J; 2013 Sep; 280(18):4396-406. PubMed ID: 23773658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
